Table 1.
Baseline and interview characteristics associated with the interaction of CAGE questionnaire results and history of injection drug use status for the participants in the LISA cohort.
| Factors | Interaction of CAGE Questionnaire Results and History of Injection Drug Use | |||
|---|---|---|---|---|
| No history of alcohol and injection drug use N = 100 |
History of alcohol or injection drug use N = 325 |
History of both alcohol and injection drug use N = 112 |
p-value | |
| Sex | ||||
| Male | 88 (88%) | 233 (72%) | 75 (67%) | <0.0001 |
| Female | 12 (12%) | 92 (28%) | 37 (33%) | |
| Baseline HAART Regimen | ||||
| Unboosted PI | 26 (26%) | 85 (26%) | 24 (21%) | 0.6554 |
| Boosted PI | 36 (36%) | 101 (31%) | 35 (31%) | |
| NNRTI | 38 (38%) | 139 (43%) | 53 (47%) | |
| Adherence to HAART (6 months before interview) | ||||
| ≥95% | 86 (86%) | 220 (68%) | 58 (52%) | <0.0001 |
| <95% | 14 (14%) | 105 (32%) | 54 (48%) | |
| Baseline Age (years) | 43 (36 – 49) | 40 (33 – 47) | 41 (36 – 45) | 0.1856 |
| CD4 cell count (cells/mm3) | ||||
| Baseline | 225 (80 – 315) | 190 (110 – 290) | 190 (145 – 350) | 0.3000 |
| At the time of interview | 500 (345 – 660) | 350 (210 – 550) | 280 (170 – 430) | <0.0001 |
| • Percent change from baseline | 128 (50 – 393) | 93 (4 – 260) | 30 (−14 – 135) | <0.0001 |
| • Difference from baseline | 260 (140 – 400) | 159 (10 – 320) | 65 (−35; – 220) | <0.0001 |
| Plasma Viral Load (log10 copies/mL) | ||||
| Baseline | 5 (4.8 – 5.0) | 5 (4.6 – 5.0) | 4.8 (4.3 – 5.0) | 0.0001 |
| • Difference from baseline | −2.3 (−2.3 – −2.0) | −2.2 (−2.3 – −1.5) | −1.7 (−2.3 – −0.6) | <0.0001 |
| Follow-up from baseline to the interview (years) | 5.2 (2.0 – 9.2) | 5.3 (2.2 – 8.8) | 3.9 (2.2 – 8.4) | 0.4067 |
NNRTI: non-nucleoside reverse transcriptase inhibitor; Boosted PI: protease inhibitor boosted with ≤400mg/day ritonavir; Unboosted PI: single protease inhibitor.